Neuroscientist Alleges Out Irregularities in Alzheimer's Res

A US neuroscientist claims that some of the studies of the experimental agent, Simufilam, a drug that targets amyloid beta in Alzheimer's disease, are flawed and has taken his concerns to the NIH.

Related Keywords

Charles Piller , Sylvain Lesne , Karen Ashe , Matthew Schrag , Sylvain Lesn , Vanderbilt University Medical Center , Lesne Laboratory , National Institutes Of Health , Simufilam Cassava Sciences , Vanderbilt University In Nashville , Vanderbilt University Or Medical Center , Cassava Sciences , University Of Minnesota , National Institutes , Vanderbilt University , Medscape Medical , Medical News , Vanderbilt University Medical , Dementia , Antidementia Agents , Amyloid Plaque , Amyloid Beta , Medical Literature , Books , Textbooks , Ournals , Alzheimers Disease , Lzheimer Disease ,